Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

NCT07080216 · tracked via the Priya Life Science China tracker

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase

Phase 1/2

Started

2025-09-23

Last updated

2026-01-05

Condition(s) studied

Cervical Cancer

Investigational drug(s) / intervention(s)

ZG005GecacitinibBevacizumab

ZG005: ZG005 20mg/kg, intravenous infusion(IV), once every 3 weeks (Q3W)

Gecacitinib: Part 1: Cohort A：Gecacitinib is administered continuously until the end of treatment; Cohort B：Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21；Part 2：Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.

Bevacizumab: Bevacizumab 7.5 mg/kg，intravenous infusion(IV), once every 3 weeks (Q3W)

Study summary

This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Fully understand the study and voluntarily sign the informed consent form. * Female 18-75 years of age; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Histologically or cytologically confirmed advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Exclusion Criteria: * Patients were deemed unsuitable for participating in the study by the investigator for any reasons.

Primary outcome measure(s)

Adverse Event (AE) — Up to 2 years
Objective response rate (ORR) — Up to 2 years

Trial sites (1)

Facility	City	Region	Status
Zhejiang Cancer Hospital	Hangzhou	Zhejiang	Recruiting

On this site

📄 Avastin (bevacizumab) drug profile →

More Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials in China

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer Recruiting

A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants. Active, not recruiting

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer Starting soon

Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma Recruiting

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors Starting soon

Other trials for the same condition

HRYZ-T101 Injection for HPV18 Positive Solid Tumor Recruiting

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease) Recruiting

A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer Starting soon

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer Recruiting

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07080216 on ClinicalTrials.gov ↗ ← All trials in China